Last reviewed · How we verify
Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) in the Treatment of Active Rheumatoid Arthritis
The primary objective of the study was to evaluate the safety and tolerability of A-319 in patients with active rheumatoid arthritis.
Details
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | RECRUITING |
| Enrolment | 12 |
| Start date | 2026-01-08 |
| Completion | 2027-08 |
Conditions
- Rheumatoid Arthritis (RA)
Interventions
- A-319
Primary outcomes
- Safety and tolerability — Time frame: Within 1 year after subcutaneous injection of A-319
Safety and tolerability will be assessed by incidence and severity of adverse events (AEs) and serious AEs (SAEs)
Countries
China